ClinicalTrials.gg
CompletedNCT05998499ELHCUpdated Aug 21, 2023

HIV-Infected Latin American Asylum Seekers in Europe: Insights From the EuroLatin HIV Cohort

An observational study in HIV-1-infection and Sexually Transmitted Diseases, sponsored by Hospital Universitario Infanta Leonor. Completed at 1 site in Spain. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by Hospital Universitario Infanta Leonor · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
631
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Sexually Transmitted Diseases with a site in Spain — 4 open to participants now, 4 under way, none of them phase 3. Sexually Transmitted Diseases · Spain.

Started
2022
with 1 other
Observational
6 of 12
3 open now
Registered
9th of 12
by date
Lead sponsor
1 of 12
Hospital Universitario Infanta Leonor

Among the 12 studies in Sexually Transmitted Diseases with a site in Spain, this one is one of 2 that started in 2022, is one of 6 observational ones, and was the 9th registered.

Sexually Transmitted Diseases

525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.

Browse Sexually Transmitted Diseases studies →

Open to participants now

4 of the 12 studies in Sexually Transmitted Diseases with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.

This study: all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Sexually Transmitted Diseases with a site in Spain, or all of them as a file.
02

Study summary

This is a longitudinal observational study conducted in Europe that describes migrants infected with HIV from Latin America who come to Europe with the intention of seeking asylum or international protection. The aim of the study is to identify the barriers this population faces in accessing the healthcare system and to assess disease control

Read the detailed description

Study Design and Setting This observational study was conducted between 2022 and 2023 in Madrid, Spain. Participants were recruited at the HIV outpatient clinic of Infanta Leonor University Hospital (HUIL) for the study and were monitored for a period of 6 months from their enrollment in the study.

Participant Recruitment Participants were primarily identified and referred by various non-governmental organizations (NGOs) working with migrants living with HIV. These NGOs, which included gTt-VIH, Apoyo Positivo, Cogam, Acción Triangulo, Kif-Kif, Salud Entre Culturas, and the Spanish Red Cross, played an essential role by establishing a crucial link and provided a vital bridge, facilitating the patients' integration into the healthcare system through an unconventional circuit.

Medical Evaluation In the HIV unit, assessments were conducted by experienced infectious disease specialists and a unit-specific nurse. The care protocol comprised a meticulous collection of medical history, an exhaustive physical examination, along with a series of tests. Furthermore, appointments were scheduled for a one-month and six-month follow-up to ensure continuous care and monitor the effectiveness of the treatment regimen.

Social and Psychological Evaluation An experienced social worker with a background in vulnerable populations was hired to perform a social assessment. Six months post the initial hospital visit, the social worker re-established contact with the patients to reassess their social circumstances and their continued engagement with the HIV consultation services.

Ethical Considerations This study adhered to the ethical principles outlined in the Declaration of Helsinki and received the necessary approvals from the ethics committee at Infanta Leonor Hospital. Informed consent was provided by every participant.

Data collection In this study, the REDCap application was utilized for the collection of data. The database was stored in a secure server, and only researchers and health personnel of the project had access to it.

03

Conditions studied

  • HIV-1-infection
  • Sexually Transmitted Diseases

Keywords

  • Asylum Seekers
  • Migration
  • Europe
  • Latin America
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Latin American migrants infected with HIV

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Latin American migrants infected with who arrive in Spain with the intent to seek international protection and who lack access to healthcare.

Exclusion criteria

Exclusion Criteria:

  • Those who do not give their consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
631 participants (actual)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • EuroLatin HIV Cohort (ELHC)

    Cohort of Latin American migrants living with HIV who were seeking international protection in Spain (Europe)

    Other: Description

Interventions

  • OtherDescription

    This study aimed to understand the situation of Latin American HIV-positive migrants seeking asylum in Spain and identify the challenges they encounter in getting HIV treatment. The main result measured was the proportion of participants with an HIV-1 RNA level of 50 copies/mL or higher at their first clinic visit

06

What researchers measure

Primary outcomes

  1. HIV viral control

    Number of participants with plasma HIV-1 RNA level of more than 50 copies per mL

    Time frame: At inclusion

Secondary outcomes

  1. Resistance Pattern

    Number of participants with Drug Resistance

    Time frame: At inclusion

  2. Sexually transmited infections

    Number of participants with sexually transmited infections

    Time frame: At inclusion

  3. Number and Type of Barriers to Accessing Healthcare

    The outcome will assess the number and type of barriers faced by study participants when trying to access healthcare, based on the presence of any of the following barriers: administrative, geographical, financial, cultural, lack of knowledge, stigma, and organizational.

    Time frame: At inclusion

  4. HIV viral control at 6 months

    Number of participants with plasma HIV-1 RNA level of more than 50 copies per mL

    Time frame: 6 months

  5. Retention in care

    Number of participants who maintain retention to healthcare

    Time frame: 6 months

07

Study locations

1 site
  • Hospital Universitario Infanta Leonor
    Madrid, 28031, Spain
08

References and documents

Individual participant data

Plan to share: Yes — IPD that underlie results in a publication

Supporting information: Study protocol

Time frame: December, 2024

Access criteria: IP email

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Apr 2023, 15 months.

Of 42 non-industry observational studies under Sexually Transmitted Diseases, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 57. This study's 15 months is below that.

Counting every sponsor, half of 48 studies reached it within 26 months; a quarter within 15 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2023
First posted
Aug 21, 2023
StartActual
Jan 30, 2022
Primary completionActual
Apr 30, 2023
CompletionActual
Jul 15, 2023
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05998499
Lead sponsor
Hospital Universitario Infanta Leonor
Responsible party
Pablo Ryan (Principal Investigator, Hospital Universitario Infanta Leonor) — Principal investigator
First posted
Aug 21, 2023
Start date
Jan 30, 2022
Primary completion
Apr 30, 2023
Completion
Jul 15, 2023
Last update
Aug 21, 2023

Study contacts

Pablo Ryan Murua, MD, PhD
principal investigator · Hospital Universitario Infanta Leonor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion